Immunohistochemical analysis of 865 tumor samples from the PORTEC‐1 and PORTEC‐2 trials showed a significant increase in the risk of distant recurrence and pelvic lymph node recurrence with high L1CAM expression.14 This evidence concerns the gene L1CAM and neoplasm.